Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: J Mol Med (Berl). 2014 Nov 22;93(4):403–412. doi: 10.1007/s00109-014-1229-z

Figure 1. Neutralization of BMP-2 diminishes biglycan-induced expression of ALP, osteopontin and Runx2.

Figure 1

Human AVICs were treated with biglycan (BGN, 0.10 μg/ml) for 3 days in the presence of a neutralizing antibody (Ab) against BMP-2 or non-immune IgG. Neutralization of BMP-2 reduces protein levels of ALP, osteopontin and Runx2 in cells treated with biglycan. n=4 isolates from different donors; *P<0.05 vs. untreated control; #P<0.05 vs. BGN alone; †P<0.05 vs. BGN+non-immune IgG.